Michigan is currently home to 2237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
Recruiting
This phase I trial investigates the side effects of chemotherapy and cellular immunotherapy in treating children with IL13Ralpha2 positive brain tumors that have come back after a period of improvement (recurrent) or do not respond to treatment (refractory). Cellular immunotherapy (IL13(EQ)BBzeta/CD19t+ T cells) are brain-tumor specific cells that may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as as cyclop... Read More
Gender:
ALL
Ages:
Between 4 years and 25 years
Trial Updated:
04/18/2025
Locations: C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan
Conditions: Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Recruiting
Purpose: About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but responses vary greatly across individuals and PTSD subpopulations. Neurobiological factors impacted by life experiences, stress, and genetics can affect treatment responses. These factors can alter brain capacities needed to reprocess traumatic memories prevent them from triggering intensely distressing, disruptive, out-of-place respons... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/18/2025
Locations: Wayne State University, Detroit, Michigan
Conditions: Post Traumatic Stress Disorder
Nephrotic Syndrome Study Network
Recruiting
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not s... Read More
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/18/2025
Locations: CS Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan
Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
University of Michigan "Nephrology Research BioBank"
Recruiting
The purpose of the study is to create a Nephrology Tissue Biobank enabling the study of kidney disease from the perspectives of epidemiology, genetics and molecular biology.
Gender:
ALL
Ages:
All
Trial Updated:
04/18/2025
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Chronic Kidney Disease
Patient-Centered Decision Support for Eosinophilic Esophagitis
Recruiting
The study team is conducting this project to learn more about how patients with eosinophilic esophagitis (EoE) like to use and receive educational materials about treatment options and treatment decision making. This study will assess the efficacy of a decision support intervention to make decisions about treatment and disease management for patients with EoE and will assess the feasibility and acceptability of the intervention to inform future R01-level studies. The study team hypothesize tha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Eosinophilic Esophagitis
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
04/16/2025
Locations: Study Site, Detroit, Michigan
Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III
IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
Recruiting
This research study is testing whether changes in sleep timing and morning light treatment may have an impact on symptoms related to inflammatory bowel disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
Recruiting
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Aortic Aneurysm, Abdominal
How Simplified Language Affects Comprehension and Learning in Young Autistic Children
Recruiting
The long-term study goal is to experimentally evaluate the components (and likely active ingredients) of early language interventions for young children with ASD. The overall objective is to determine how single-word and telegraphic simplification affects real-time language processing and word learning in young children with ASD (relative to full, grammatical utterances). The proposed project will investigate three specific aims: 1) Determine how single-word and telegraphic simplification affect... Read More
Gender:
ALL
Ages:
Between 1 year and 4 years
Trial Updated:
04/16/2025
Locations: Michigan State University, East Lansing, Michigan
Conditions: Autism Spectrum Disorder
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Recruiting
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Gender:
ALL
Ages:
59 months and below
Trial Updated:
04/16/2025
Locations: C.S. MOTT Children's Hospital, University of Michigan, Ann Arbor, Michigan
Conditions: Medulloblastoma
Longitudinal Oral Microbiome Sampling for BE
Recruiting
This is a longitudinal cohort study to assess the impact of repeated sampling of an oral microbiome signature for Barrett's esophagus (BE). Potential participants will be identified through chart review of patients who have had an endoscopy in the past three years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Barrett Esophagus
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
Recruiting
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, m... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan
Conditions: Metastatic Castration Resistant Prostate Cancer